Representatives of Scope Fluidics S.A. are set to participate in the 41st Annual J.P. Morgan Healthcare Conference due to take place in mid-January next year in San Francisco, USA. Organised by one of the world’s largest investment banks, the meeting is the largest event of its kind bringing together investors, leaders and developers of cutting-edge technologies in the field of life science.
“The invitation for Scope Fluidics’ to the prestigious J.P. Morgan conference is a great honour for our team, and at the same time an opportunity to increase the company’s visibility and to present our innovative technologies to an international forum of investors and experts in the life science industry. This is undoubtedly the result of our success in selling our PCR|ONE technology for a total of USD 170 million to the US company Bio-Rad Laboratories – a world leader in the field of bioanalytical techniques. Our success was also recognised by Forbes Poland magazine, which awarded Scope Fluidics with the title of the Stock Exchange Company of the Year 2022 during its 7th Congress of Polish Capital” – says Piotr Garstecki, CEO of Scope Fluidics S.A.
The J.P Morgan Health Care Conference takes place from 9-12 January 2023 in San Francisco.
